Review

oga (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech oga
Oga, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 126 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oga/OGT+Antibody/pm41935067-260-19-20
Average 96 stars, based on 126 article reviews

oga - by Bioz Stars, 2026-10

96/100 stars

Images

Incubation:

Article Title: Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil.
Article Snippet: Subsequently, the slides were incubated with 3% hydrogen peroxide solution (Boster, AR1108) for 10 minutes at room temperature to quench endogenous peroxidase activity, then blocked with 5% BSA (in PBS) for 30 minutes to minimize non-specific binding. .. AR TI CL E IN P RE SS Primary antibodies, including TYMS (Proteintech, 15047-1-AP, 1:200), OGT (Proteintech, 11576-2-AP, 1:200), OGA (Proteintech, 14711-1-AP, 1:200), Ki-67 (ZSGB-Bio, ZM-0167, 1:1), and pS2448-mTOR (Proteintech, 67778-1-1G, 1:200), were diluted in 1% BSA and incubated overnight at 4°C. .. After washing, the slides were incubated with the appropriate secondary antibodies (Peroxidase AffiniPure Goat Anti-Mouse IgG, Jackson ImmunoResearch, 115-035-003, 1:200; Peroxidase AffiniPure Goat Anti-Rabbit IgG, Jackson ImmunoResearch, 111-035-003, 1:200) for 1 hour at room temperature.

Article Title: O-GlcNAcylation regulates microglial neuroinflammation in Parkinson's disease.
Article Snippet: Western Blotting AR TI CL E IN P RE SS Equal amounts of protein (30 μg) were separated on 10% or 15% SDS-PAGE gels and transferred to nitrocellulose membranes (Amersham). .. Membranes were blocked with 5% nonfat milk in PBST for 1 h at room temperature, then incubated overnight at 4°C with primary antibodies (1:1,000) against various targets, including O-GlcNAc (sc-59623, RL2, Santa Cruz, Dallas, TX, USA), OGT (sc-74546, Santa Cruz), OGA (14771-1-AP, Proteintech, Rosemont, IL, USA), GFAT2 (A15374, Abclonal, Woburn, MA, USA) tyrosine hydroxylase (T2928,TH, Sigma-Aldrich), β-actin (sc28365, Santa Cruz), p-p65 (ab86229, Abcam, Cambridge, UK), p65 (sc-8008, Santa Cruz), p-IκB (sc-8404, Santa Cruz), IκB (sc-371, Santa Cruz), iNOS (610328, BD Bioscience, San Jose, CA, USA), COX2 (A3560, Abclonal), p-CREB (ab32096, Abcam), CREB (sc-377154, Santa Cruz), TLR4 (A0007, Abclonal), Arg1 (A4923, Abclonal), CD163 (A26411PM, Abclonal), CD86 (A16805, Abclonal), CD63 (A6554, Abclonal), c-Rel (sc-6955, Santa Cruz), p-STAT3 (9145, Cell Signaling Technology, Danvers, MA, USA), STAT3 (sc-8019, Santa Cruz), p-ERK (9101, Cell Signaling Technology), ERK (A16686, Abclonal), PPARγ (sc-7273, Santa Cruz), NLRP3 (sc134306, Santa Cruz), ASC (sc-514414, Cell Signaling Technology), cleaved caspase 1 (89332, Cell Signaling Technology), and caspase 1 (24232, Cell Signaling Technology). .. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (Invitrogen) for 1 h at RT.

Article Title: O-GlcNAcylation stabilizes c-MYC to upregulate xCT and inhibit ferroptosis in ovarian cancer.
Article Snippet: .. Membranes were then blocked in 5 % skim milk for 2 h and incubated overnight with primary antibodies to RL2 (Abcam, UK; ab2739, 1:1000), OGT (Proteintech, China; 11576-2-AP, 1:2000), GFAT (Proteintech, China; 14132-1-AP,1:1000), OGA (Proteintech, China; 14711-1-AP, 1:2000), xCT (Abmart, China; T57046, 1:1000), GPX4 (Abmart, China; T56959, 1:1000), FTH (Abclonal, China, A19544, 1:1000), TFR1 (Abclonal, China, A5865, 1:1000), ACSL4 (Proteintech, China; 22401-1-AP, 1:4000), c-MYC (Proteintech, China; 10828-1-AP, 1:5000), and Beta-actin (Proteintech, China; 66009-1-Ig, 1:4000). .. The next day, membranes were washed, incubated at room temperature with secondary antibodies (Proteintech, China; SA00001-2, 1:4000 or SA00001-1, 1:3000) for 1 h, and displayed using an enhanced chemiluminescent kit (Thermo Fisher Scientific, USA). β-Actin was used as an internal control for normalization to determine protein expression levels.

Article Title: A Novel Missense Variant in Ultrarare SLC35A1-CDG Alters Cellular Glycosylation, Lipid, and Energy Metabolism Without Affecting CDG Serum Markers
Article Snippet: .. Primary antibodies for detection of SLC35A1 (Proteintech, BIOZOL, MyBioSource), ADAMTS13, ATP5H, GP130 (all Thermo Fisher), GAPDH, histone 2B (H2B), H2B-GlcNAc (all Abcam), ICAM1 (Sigma), OGA, OGT, TGN46 (all Proteintech), O-GlcNAcylation (Santa Cruz), and HA-Tag (Sigma) were used in 1:1000 dilution, β -ACTIN (Sigma) in 1:10,000 dilution, and incubated overnight at 4°C under constant movement. .. Secondary antibodies used were anti-rabbit IgG-conjugated with horseradish peroxidase (HRP) (for SLC35A1, ADAMTS13, H2B, H2B-GlcNAc, ICAM1, GP130, OGA, OGT, TGN46, and HA-Tag) from Dianova or anti-mouse IgG-HRP (for β -actin, GAPDH, O-GlcNAcylation, and ATP5H) from Santa Cruz in a dilution of 1:10,000.

Article Title: LIMA1 O‐GlcNAcylation Promotes Hepatic Lipid Deposition through Inducing β‐catenin‐Regulated FASn Expression in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Article Snippet: .. Next, the membrane was blocked with 5% milk at room temperature for 1 h. The membrane with blotted protein was incubated with primary antibodies against β‐actin (Abclonal, Wuhan, China, AC006), LIMA1 (Proteintech, Wuhan, China, 66071‐1‐Ig), O‐GlcNAc (Cell Signaling Technology, USA, 9875S), β‐catenin (Proteintech, Wuhan, China, 17565‐1‐AP), FASn (Proteintech, Wuhan, China, 10624‐2‐AP), OGT (Proteintech, Wuhan, China, 66823‐1‐Ig), OGA (Proteintech, Wuhan, China, 14711‐1‐AP), HCF1 (Cell Signaling Technology, USA, 50708S), DYKDDDDK tag (Proteintech, Wuhan, China, 66008‐4‐Ig), MYC tag (Proteintech, Wuhan, China, 60003‐2‐Ig), His tag (Proteintech, Wuhan, China, 66005‐1‐Ig), HA tag (Proteintech, Wuhan, China, 51064‐2‐AP), ALIX (Proteintech, Wuhan, China, 12422‐1‐AP), TSG101 (Proteintech, Wuhan, China, 28283‐1‐AP), CD9 (Cell Signaling Technology, USA, 98327S), CD63 (Cell Signaling Technology, USA, 52090S), Calnexin (Proteintech, Wuhan, China, 10427‐2‐AP), α‐SMA (Proteintech, Wuhan, China, 55135‐1‐AP), and Col3A1 (Proteintech, Wuhan, China, 22734‐1‐AP). .. Following this, the membrane was probed with horseradish peroxidase‐conjugated secondary antibodies (Invitrogen, USA, 31 460) and the protein bands were visualized using enhanced chemiluminescence reagents (Vazyme, Nanjing, China, E412‐01).

Article Title: Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction.
Article Snippet: In brief Tatekoshi et al. describe that hexokinase (HK) 1 mitochondrial dislocation drives endothelial dysfunction and heart failure with preserved ejection fraction (HFpEF).. HK1 subcellular localization regulates the supply of hexosamine biosynthetic pathway products, balancing N-glycosylation and O-GlcNAcylation.. Inhibition of O-linked Nacetylglucosamine-transferase (OGT) with 5S-GlcNHex mitigates HFpEF, highlighting a potential therapeutic strategy.

Membrane:

Ubiquitin Proteomics:

Article Title: Dynamic O-GlcNAcylation coordinates etoposide-triggered tumor cell pyroptosis by regulating p53 stability
Article Snippet: .. GSDME (Abcam, 215191); caspase-3 (Abcam, 184787); O-GlcNAc (Invitrogen, MA1-072); GAPDH (Proteintech, 60004-1-Ig); Goat anti-mouse IgG (Proteintech, SA00001–1); Goat anti-rabbit IgG (Proteintech, SA00001–2); α-Tubulin (Abcam, ab176560); P53 (Proteintech, 10442-1-AP); Rabbit anti-mouse IgG (Light Chain Specific) (Cell Signaling Technology, 58802S); Mouse anti-rabbit IgG (Conformation Specific) (Cell Signaling Technology, 5127S), Ubiquitin mouse mAb (Cell Signaling Technology, 3936S); OGA (Proteintech, 14711-1-AP); OGT (Proteintech, 11576-2-AP); MDM2 (Abcam, ab259265); DYKDDDDK tag antibody (Cell Signaling Technology, 2368S). .. The following beads were used in these immunoprecipitation analyses: Anti-DYKDDDDK Magnetic Agarose (Thermo Scientific, A36798); Succinylated WGA Agarose (Vector, AL-1023S); Dynabeads Protein A (Thermo Scientific, 10002D).

Image Search Results

Inhibition of OGT downregulates the c-Myc pathway in HUVECs. HUVECs were transfected with 20 nM OGT siRNA1, siRNA2 or siRNA negative control for 6 h and cultured for another 48 h. The gene expressions of (A) OGT, (B) OGA and (C) c-Myc were detected using reverse transcription-quantitative PCR. (D) OGT, OGA and c-Myc protein expression levels were assessed using western blotting and (E) semi-quantified. (F) Cell viability was analyzed via Cell Counting Kit-8 assay. n=3; **P<0.01 compared with siRNA control group. HUVECs, human umbilical vein endothelial cells; OGT, O-linked N-acetylglucosamine transferase 110 kDa subunit; OGA, β-N-acetylglucosaminidase; siRNA, small interfering RNA.

Journal: Molecular Medicine Reports

Article Title: miRNA-29a inhibits the proliferation of HUVECs by regulating the ITGB1/β-catenin/c-Myc pathway

doi: 10.3892/mmr.2026.13825

Figure Lengend Snippet: Inhibition of OGT downregulates the c-Myc pathway in HUVECs. HUVECs were transfected with 20 nM OGT siRNA1, siRNA2 or siRNA negative control for 6 h and cultured for another 48 h. The gene expressions of (A) OGT, (B) OGA and (C) c-Myc were detected using reverse transcription-quantitative PCR. (D) OGT, OGA and c-Myc protein expression levels were assessed using western blotting and (E) semi-quantified. (F) Cell viability was analyzed via Cell Counting Kit-8 assay. n=3; **P<0.01 compared with siRNA control group. HUVECs, human umbilical vein endothelial cells; OGT, O-linked N-acetylglucosamine transferase 110 kDa subunit; OGA, β-N-acetylglucosaminidase; siRNA, small interfering RNA.

Article Snippet: The membranes were blocked with 5% skimmed milk for 1 h at room-temperature and incubated with the following primary antibodies overnight at 4°C: ITGB1 (cat. no. 12594-1-AP; Proteintech Group, Inc.), T-cell factor 1 (TCF1; cat. no. 14464-1-AP; Proteintech Group, Inc.), EZH2 (cat. no. ab307646; Abcam), c-Myc (cat. no. 67447-1-Ig; Proteintech Group, Inc.), phosphorylated (p-)GSK3β (cat. no. AF2016; Affinity Biosciences), GSK3β (cat. no. AF5016; Affinity Biosciences), p-β-catenin (cat. no. DF2989; Affinity Biosciences), β-catenin (cat. no. 17565-1-AP; Proteintech Group, Inc.), β-actin (cat. no. 66009-1-Ig; Proteintech Group, Inc.), OGT (cat. no. ab177941; Abcam) and OGA (cat. no. DF8436; Affinity Biosciences).

Techniques: Inhibition, Transfection, Negative Control, Cell Culture, Reverse Transcription, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Cell Counting, Control, Small Interfering RNA

miR-29a downregulates the β-catenin/c-Myc pathway in HUVECs by targeting ITGB1. HUVECs were transfected with 20 µg/ml miR-29a mimics, miR-29a inhibitor or negative control for 6 h and cultured for another 48 h. (A) The protein expression levels of OGT, OGA, ITGB1, TCF1, c-Myc, p-GSK3β, GSK3β, p-β-catenin and β-catenin were assessed using western blotting and (B) semi-quantified. p-GSK3β and p-β-catenin were normalized to the levels of total GSK3β or β-catenin, respectively. (C) Cell viability was analyzed using a Cell Counting Kit-8 assay. The interaction between miR-29a and ITGB1 was validated using (D) TargetScan and (E) via dual-luciferase reporter assay (**P<0.01 compared with miR NC + ITGB1 WT group). (F) A schematic figure illustrating the interactions among miR-29a, ITGB1 and the c-Myc pathway. n=3; *P<0.05 and **P<0.01 compared with miRNA-NC group. miR/miRNA, microRNA; HUVECs, human umbilical vein endothelial cells; ITGB1, integrin β1; OGT, O-linked N-acetylglucosamine transferase 110 kDa subunit; OGA, β-N-acetylglucosaminidase; TCF1, T-cell factor 1; p- phosphorylated; hsa-miR, human microRNA; NC, negative control; WT, wild-type; Mut, mutant.

Journal: Molecular Medicine Reports

Article Title: miRNA-29a inhibits the proliferation of HUVECs by regulating the ITGB1/β-catenin/c-Myc pathway

doi: 10.3892/mmr.2026.13825

Figure Lengend Snippet: miR-29a downregulates the β-catenin/c-Myc pathway in HUVECs by targeting ITGB1. HUVECs were transfected with 20 µg/ml miR-29a mimics, miR-29a inhibitor or negative control for 6 h and cultured for another 48 h. (A) The protein expression levels of OGT, OGA, ITGB1, TCF1, c-Myc, p-GSK3β, GSK3β, p-β-catenin and β-catenin were assessed using western blotting and (B) semi-quantified. p-GSK3β and p-β-catenin were normalized to the levels of total GSK3β or β-catenin, respectively. (C) Cell viability was analyzed using a Cell Counting Kit-8 assay. The interaction between miR-29a and ITGB1 was validated using (D) TargetScan and (E) via dual-luciferase reporter assay (**P<0.01 compared with miR NC + ITGB1 WT group). (F) A schematic figure illustrating the interactions among miR-29a, ITGB1 and the c-Myc pathway. n=3; *P<0.05 and **P<0.01 compared with miRNA-NC group. miR/miRNA, microRNA; HUVECs, human umbilical vein endothelial cells; ITGB1, integrin β1; OGT, O-linked N-acetylglucosamine transferase 110 kDa subunit; OGA, β-N-acetylglucosaminidase; TCF1, T-cell factor 1; p- phosphorylated; hsa-miR, human microRNA; NC, negative control; WT, wild-type; Mut, mutant.

Techniques: Transfection, Negative Control, Cell Culture, Expressing, Western Blot, Cell Counting, Luciferase, Reporter Assay, Mutagenesis

OGA inhibitors alter synaptic plasticity. A , sample traces of whole-cell patch clamp recording of hippocampal CA1 pyramidal neurons during the first episode of paired-pulse stimulation ( A1 ) and aligned first response from every episode ( A2 ). Scale bar, 20 ms (horizontal) and 0.5pA (vertical). The color coding for DMSO (black), ASN90 ( i.e. , ASN, red), LY3372689 ( i.e. , LY, green), and MK8719 ( i.e. , MK, blue) is used in all plots. B , plots of EPSC ratio for the responses during the first episode ( B1 ) and the first responses of five episodes ( B2 ). C , LTP measured as relative EPSP slopes after the treatments of OGAi or DMSO. Left insets are sample traces pre- and post 100-Hz 1-s tetanus stimulation. Right inset is a violin plot of the average values during the last 30-s recording ( i.e. , gray box in the plot). Welch’s ANOVA test, W (DFn, DFd) = 10.61 (3.000, 17.50), p = 0.0003; Kolmogorov-Smimov test, p = 0.0063 (ASN vs. DMSO), 0.0336 (LY vs. DMSO), and 0.0063 (MK vs. DMSO). N = 3 mice and n = 3 slices ( i.e. , 9 recordings in total for every treatment). *, 0.05 > p ≥ 0.01; **, 0.01 > p ≥ 0.005; ***, 0.005 > p ≥ 0.001, ****, p < 0.001.

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Synaptic toxicity of OGA inhibitors and the failure of ceperognastat

doi: 10.1016/j.tjpad.2025.100456

Figure Lengend Snippet: OGA inhibitors alter synaptic plasticity. A , sample traces of whole-cell patch clamp recording of hippocampal CA1 pyramidal neurons during the first episode of paired-pulse stimulation ( A1 ) and aligned first response from every episode ( A2 ). Scale bar, 20 ms (horizontal) and 0.5pA (vertical). The color coding for DMSO (black), ASN90 ( i.e. , ASN, red), LY3372689 ( i.e. , LY, green), and MK8719 ( i.e. , MK, blue) is used in all plots. B , plots of EPSC ratio for the responses during the first episode ( B1 ) and the first responses of five episodes ( B2 ). C , LTP measured as relative EPSP slopes after the treatments of OGAi or DMSO. Left insets are sample traces pre- and post 100-Hz 1-s tetanus stimulation. Right inset is a violin plot of the average values during the last 30-s recording ( i.e. , gray box in the plot). Welch’s ANOVA test, W (DFn, DFd) = 10.61 (3.000, 17.50), p = 0.0003; Kolmogorov-Smimov test, p = 0.0063 (ASN vs. DMSO), 0.0336 (LY vs. DMSO), and 0.0063 (MK vs. DMSO). N = 3 mice and n = 3 slices ( i.e. , 9 recordings in total for every treatment). *, 0.05 > p ≥ 0.01; **, 0.01 > p ≥ 0.005; ***, 0.005 > p ≥ 0.001, ****, p < 0.001.

Article Snippet: As Biogen’s Phase I BIIB113 study [ ] highlighted, potential impacts on synaptic transmission should be considered in the design and interpretation of clinical OGA inhibitor programs.

Techniques: Patch Clamp

OGA inhibitors alter synaptic protein levels and Tau phosphorylation. A , sample images of fluorescence immunocytochemistry for PSD95, Tuj1, GFAP, and DAPI. Scale bar, 0.5 mm. Images on the left are zoom-in images of PSD95 immunofluorescence in the cell-body layer (indicated by the white box) for all four treatments. Scale bar, 50 μm B , sample images of fluorescence immunocytochemistry for Synaptophysin 1, Tau, pTau, and DAPI. Images on the left are zoom-in images of Synaptophysin 1 immunofluorescence in the cell-body layer (indicated by the white box) for all four treatments. C & D , violin plots of PSD95 ( C ) and Synaptophysin 1 ( D ) immunofluorescence intensities. E , violin plots of pTau vs. Tau fluorescence intensity (F) ratios from the same ROIs of Synaptophysin 1. Welch’s ANOVA test for PSD95, W (DFn, DFd) = 90.96 (3.000, 2168), p < 0.0001; for Synaptophysin 1 fluorescence intensity, W (DFn, DFd) = 153.30 (3.000, 2187), p < 0.0001; for pTau/Tau, W (DFn, DFd) = 128.40 (3.000, 1918), p < 0.0001. Kolmogorov-Smimov test for all three, p < 0.0001 (ASN vs. DMSO, LY vs. DMSO, and MK vs. DMSO). N = 9 slices from 3 mice (3 ea), n = 999 ROIs (111 randomly selected from every slice). *, 0.05 > p ≥ 0.01; **, 0.01 > p ≥ 0.005; ***, 0.005 > p ≥ 0.001, ****, p < 0.001.

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Synaptic toxicity of OGA inhibitors and the failure of ceperognastat

doi: 10.1016/j.tjpad.2025.100456

Figure Lengend Snippet: OGA inhibitors alter synaptic protein levels and Tau phosphorylation. A , sample images of fluorescence immunocytochemistry for PSD95, Tuj1, GFAP, and DAPI. Scale bar, 0.5 mm. Images on the left are zoom-in images of PSD95 immunofluorescence in the cell-body layer (indicated by the white box) for all four treatments. Scale bar, 50 μm B , sample images of fluorescence immunocytochemistry for Synaptophysin 1, Tau, pTau, and DAPI. Images on the left are zoom-in images of Synaptophysin 1 immunofluorescence in the cell-body layer (indicated by the white box) for all four treatments. C & D , violin plots of PSD95 ( C ) and Synaptophysin 1 ( D ) immunofluorescence intensities. E , violin plots of pTau vs. Tau fluorescence intensity (F) ratios from the same ROIs of Synaptophysin 1. Welch’s ANOVA test for PSD95, W (DFn, DFd) = 90.96 (3.000, 2168), p < 0.0001; for Synaptophysin 1 fluorescence intensity, W (DFn, DFd) = 153.30 (3.000, 2187), p < 0.0001; for pTau/Tau, W (DFn, DFd) = 128.40 (3.000, 1918), p < 0.0001. Kolmogorov-Smimov test for all three, p < 0.0001 (ASN vs. DMSO, LY vs. DMSO, and MK vs. DMSO). N = 9 slices from 3 mice (3 ea), n = 999 ROIs (111 randomly selected from every slice). *, 0.05 > p ≥ 0.01; **, 0.01 > p ≥ 0.005; ***, 0.005 > p ≥ 0.001, ****, p < 0.001.

Techniques: Phospho-proteomics, Fluorescence, Immunocytochemistry, Immunofluorescence

Review

oga (Proteintech)

Structured Review

Images

Related Articles

Incubation:

Membrane:

Ubiquitin Proteomics:

Similar Products

Image Search Results